Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2007-11-08
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this study are:

• To determine the overall response rate of patients treated with at least 2 cycles of this regimen.

• To determine the feasibility and toxicity of the combination of topotecan and docetaxel.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aultman Health Foundation; Aultman Hospital
• Collaborator: GlaxoSmithKline
• Treatments: Docetaxel; Topotecan

Criteria

Inclusion Criteria:

• Recurred greater than 90 days after initial treatment

• At least 1 measurable lesion

• Only 1 prior chemotherapy

• Must be over 18 years of age

• ECOG performance status of 0 - 2

• Adequate hematologic, renal, and hepatic function

Exclusion Criteria:

• No prior use of topotecan, docetaxel, or irinotecan

• No symptomatic brain metastases

• History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events

• No prior investigational agents within 1 month prior

• Lung cancer of mixed histology

• Known uncontrolled seizure disorders